Article

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner

2023-03-17

Abstract excerpt

<title>Abstract</title> <p>Background <italic>KRAS</italic> activating mutations are considered the most frequent oncogenic drivers and are correlated with radio-resistance in multiple cancers including non-small cell lung cancer (NSCLC) and colorectal cancer. Although KRAS was considered undruggable until recently, several KRAS inhibitors have recently reached clinical development. Among them, MRTX849 (Mirati T...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c261c606-e415-56a3-8081-047fb147343a
DOI: 10.21203/rs.3.rs-2677744/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partnerDOI 10.21203/rs.3.rs-2677744/v1Read

KRASG12C inhibition using MRTX1257: a novel radio-sensitizing partner.Semantic proximity Read

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapySemantic proximity Read

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Semantic proximity Read

Evaluation of KRAS <sup>G12C</sup> Inhibitor Responses in Novel Murine KRAS <sup>G12C</sup> Lung Cancer Cell Line ModelsSemantic proximity Read

Radio-sensitization of mutated KRAS G12C non-small cell lung cancer with KRAS G12C tyrosine kinase inhibitor and Carbon ions irradiationSemantic proximity Read

Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation.Semantic proximity Read

Pixantrone confers radiosensitization in KRAS mutated cancer cells by suppression of radiation-induced prosurvival pathways.Semantic proximity Read

Targeting K-Ras-mediated DNA damage response in radiation oncology: Current status, challenges and future perspectivesSemantic proximity Read

Therapeutic KRAS <sup>G12C</sup> inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancersSemantic proximity Read

Radiosensitization of Glioblastoma by the K-ras Inhibitor RMC-6236Semantic proximity Read

Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.Semantic proximity Read

Inhibitor of the nuclear transport protein XPO1 enhances the anticancer efficacy of KRAS G12C inhibitors in preclinical models of KRAS G12C mutant cancersSemantic proximity Read